目的 探讨细胞视黄酸结合蛋白-Ⅰ(CRABP-Ⅰ)在成人烟雾病血清中的表达及其与术后血流动力学变化的关系。方法 选择烟雾病患者52例和健康体检者20例,采用酶联免疫吸附法分别检测烟雾病患者术前、术后6个月和健康体检者CRABP-Ⅰ的血清浓度,并与患者手术前后脑血流灌注状态进行相关性分析。结果 与对照组[(19.70±5.10) mg/L]相比,烟雾病患者CRABP-Ⅰ术前[(35.38±6.05) mg/L]及术后[(28.38±4.46) mg/L]均显著升高(P＜0.01)。术后CRABP-Ⅰ的水平较术前显著降低(P＜0.01)。铃木分期1~2期及3~4期患者术后6个月CRABP-Ⅰ水平均较术前显著降低[(28.17±4.88)mg/L vs (37.75±5.66)mg/L,P＜0.01],其中铃木分期3～4期术前CRABP-Ⅰ的血清表达显著高于铃木分期1～2期(P＜0.01)。烟雾病术后患者rTTP较术前显著降低(P=0.001)。手术前后血清CRABP-Ⅰ浓度与rTTP值均呈显著正相关(P＜0.01)。结论 CRABP-Ⅰ可能参与了烟雾病的发生发展过程,可作为烟雾病的血清学标志及血流动力学改善的指标。
Abstract
Objective To investigate the expressions of serum CRABP-Ⅰ in adults with moyamoya disease and the postoperative changes of hemodynamics.Methods Serum levels of CRABP-Ⅰ in 52 patients with moyamoya disease were measured by ELISA before operation and 6 months after operation. Serum samples from 20 healthy volunteers were taken as control. The correlations between serum levels of CRABP-Ⅰ and cerebral blood perfusion before and after operation were analyzed.Results Compared with the control group, the serum levels of CRABP-Ⅰ in moyamoya disease patients were increased significantly both before and after operation [(19.70±5.10) mg/L vs (35.38±6.05) mg/L, (28.38±4.46) mg/L; P<0.01)]. These levels decreased significantly after operation (P<0.01). The serum CRABP-Ⅰ concentrations in patients at Suzuki stage 1-2 and 3-4 were significantly lower 6 months after operation[(28.17±4.88) mg/L vs (37.75±5.66) mg/L, P<0.01)]. The serum CRABP-Ⅰ concentrations in patients at Suzuki stage 3-4 were significantly higher than those in patients at Suzuki stage 1-2 (P<0.01). The postoperative rTTP of patients was significantly lower after operation (P=0.001). The preoperative and postoperative serum CRABP-Ⅰ concentrations were positively correlated with rTTP (P<0.01).Conclusion CRABP-Ⅰ may be involved in the occurrence and development of moyamoya disease and can be used as a serological marker and indicator of hemodynamic improvement.
关键词
烟雾病 /
CRABP-Ⅰ /
磁共振灌注成像
Key words
moyamoya disease /
CRABP-Ⅰ /
magnetic resonance perfusion imaging
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Shang S, Zhou D, Ya J, et al. Progress in moyamoya disease[J]. Neurosurg Rev, 2018, 70(4):229-230.
[2] Smith E R. Moyamoya Biomarkers[J]. J Korean Neurosurg Soc, 2015,57(6):415-421.
[3] Jeon J P, Cho W S, Kang H S, et al. Elevated cellular retinoic Acid binding protein-I in cerebrospinal fluid of patients with hemorrhagic cerebrovascular diseases : preliminary study[J]. J Korean Neurosurg Soc, 2015,57(2):88-93.
[4] Kim S K, Yoo J I, Cho B K, et al. Elevation of CRABP-Ⅰ in the cerebrospinal fluid of patients with moyamoya disease[J]. Stroke, 2003,34(12):2835-2841.
[5] Hishikawa T, Sugiu K, Date I. Moyamoya disease: a review of clinical research[J]. Acta Med Okayama, 2016,70(4):229-236.
[6] Hu J, Luo J, Chen Q. The susceptibility pathogenesis of moyamoya disease[J]. World Neurosurg, 2017,101:731-741.
[7] Jeon J S, Ahn J H, Moon Y J, et al. Expression of cellular retinoic acid-binding protein-Ⅰ (CRABP-Ⅰ) in the cerebrospinal fluid of adult onset moyamoya disease and its association with clinical presentation and postoperative haemodynamic change[J]. J Neurol Neurosurg Psychiatry, 2014,85(7):726-731.
[8] Fiorella P D, Giguère V, Napoli J L. Expression of cellular retinoic acid-binding protein (type II) in Escherichia coli. Characterization and comparison to cellular retinoic acid-binding protein (type I) [J]. J Biol Chem, 1993,268(29):21545-21552.
[9] Choi H S, Kim DS, Shim KW, et al. Focal time-to-peak changes on perfusion MRI in children with moyamoya disease: correlation with conventional angiography[J]. Acta Radiol, 2011,52(6):675-679.
[10] Lee S, Yun T J, Yoo R E, et al. Monitoring cerebral perfusion changes after revascularization in patients with moyamoya disease by using arterial spin-labeling MR imaging[J]. Radiology, 2018,288(2):565-572.
[11] Zhang J, Xia C, Liu Y, et al. Comparative study of MR mTI-ASL and DSC-PWI in evaluating cerebral hemodynamics of patients with moyamoya disease[J]. Medicine (Baltimore), 2018,97(41):e12768.
[12] Fujimura M, Bang O Y, Kim J S. Moyamoya disease[J]. Front Neurol Neurosci, 2016,40:204-220.
[13] Acker G, Fekonja L, Vajkoczy P. Surgical management of moyamoya disease[J]. Stroke, 2018,49(2):476-482.
[14] Lee SU, Oh C W, Kwon O K, et al. Surgical treatment of adult moyamoya disease[J]. Curr Treat Options Neurol, 2018,20(7):22.
[15] Dai D W, Zhao W Y, Zhang Y W, et al. Role of CT perfusion imaging in evaluating the effects of multiple burr hole surgery on adult ischemic Moyamoya disease[J]. Neuroradiology, 2013,55(12):1431-1438.
PDF(591 KB)
